Patents by Inventor Johannes Platzek

Johannes Platzek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220098201
    Abstract: Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2, -f] [1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.
    Type: Application
    Filed: January 27, 2020
    Publication date: March 31, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg GRIES, Johannes PLATZEK, Claus-Christian HÄSELHOFF, Kai LOVIS
  • Patent number: 11274110
    Abstract: A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 15, 2022
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Gries, Johannes Platzek
  • Publication number: 20210253573
    Abstract: The present invention covers a method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (“the compound of formula (I)” in the following) as well as intermediate compounds useful in the preparation of the compound of formula (I). The present invention also covers polymorphic form B of the compound of formula (I) with very high purity.
    Type: Application
    Filed: August 22, 2019
    Publication date: August 19, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Philipp RUBENBAUER, Hendricus Nicolaas Sebastiaan VAN DER HAAS, Sonja Elisabeth HOOGEVEEN, Matthijs Cornelis Maria VAN OERS, Reinerus Gerardus GIELING, Jeroen Alexander DEKKER
  • Publication number: 20210163474
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also to the preparation of the enantiomer (Ia) by racemate resolution using chiral substituted tartaric acid esters of the general formulae (IIIa) and (IIIb) where Ar represents a substituted or unsubstituted aromatic or heteroaromatic radical.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 3, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Johannes PLATZEK, Kai LOVIS, Winfried JOENTGEN
  • Publication number: 20210024490
    Abstract: The present invention relates to a novel method for preparing (4R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula 4R (I) and the metabolites of (4S)- and (4R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I), the formulae M1a (S), M1b (R), M2a (S), M2b (R), M3a (S) and M3b (R) and use thereof.
    Type: Application
    Filed: October 14, 2020
    Publication date: January 28, 2021
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Johannes Platzek, Ludwig Zorn
  • Publication number: 20210009534
    Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 14, 2021
    Inventors: Johannes PLATZEK, Wilhelm TRENTMANN
  • Publication number: 20200353104
    Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventors: MARKUS BERGER, JESSICA LOHRKE, CHRISTOPH-STEPHAN HILGER, GREGOR JOST, THOMAS FRENZEL, DETLEV SUELZLE, JOHANNES PLATZEK, OLAF PANKNIN, HUBERTUS PIETSCH
  • Publication number: 20200339606
    Abstract: A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 29, 2020
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg GRIES, Johannes PLATZEK
  • Patent number: 10793532
    Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 6, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 10759758
    Abstract: The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: September 1, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Patent number: 10722601
    Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 28, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
  • Patent number: 10633365
    Abstract: The present invention relates to a novel method of preparing a 2-substituted indazole of formula (I) to novel intermediate compounds, and to the use of intermediate compounds for the preparation of said 2-substituted indazole.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: April 28, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Patent number: 10501417
    Abstract: The present invention relates to a novel method of preparing a 2-substituted indazole of structure: (I), to intermediate compounds, and to the use of intermediate compounds for the preparation of said 2-substituted indazole.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 10, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Patent number: 10501437
    Abstract: The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 10, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Patent number: 10435417
    Abstract: A process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration is described. The process is carried out using specifically controlled crystallization conditions.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 8, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 10399977
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also the preparation and use of the crystalline polymorph I of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I).
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Johannes Platzek, Gunnar Garke, Alfons Grunenberg
  • Patent number: 10392384
    Abstract: The present invention relates to a novel process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and recovering (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) proceeding from (4R)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula ent-(I)
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 27, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Johannes Platzek, Kathrin Gottfried, Jens Assmann, Giulio Lolli
  • Publication number: 20190210979
    Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.
    Type: Application
    Filed: September 11, 2017
    Publication date: July 11, 2019
    Inventors: Johannes PLATZEK, Wilhelm TRENTMANN
  • Patent number: 10336749
    Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I)
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: July 2, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventor: Johannes Platzek
  • Publication number: 20190152944
    Abstract: The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 23, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias THALER, Johannes PLATZEK, Nicolas GUIMOND